BOTOTLSJU
FHTX icon

Board of Trustees of The Leland Stanford Junior University’s Foghorn Therapeutics FHTX Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,657
Closed -$404K – 38
2021
Q1 		$404K Hold
30,657
– – 0.04% 23
2020
Q4 		$621K Buy
+30,657
New +$587K 0.04% 16

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's FHTX Position: Q2 2021 in Review

Board of Trustees of The Leland Stanford Junior University sold out of Foghorn Therapeutics (FHTX) in Q2 2021, closing a stake of 30,657 shares — an estimated $404K sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in FHTX in Q4 2020 and held it in 2 quarters. The position peaked at $621K in Q4 2020. 39 funds tracked by Wall St. Rank hold FHTX as of Q2 2021.

  • Board of Trustees of The Leland Stanford Junior University reported no remaining Foghorn Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Board of Trustees of The Leland Stanford Junior University sold 30,657 Foghorn Therapeutics shares in Q2 2021, an estimated $404K.
  • Board of Trustees of The Leland Stanford Junior University first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 2 quarters.
  • Board of Trustees of The Leland Stanford Junior University's Foghorn Therapeutics position peaked at $621K in Q4 2020.
  • 39 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2021.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q2 2021, filed 16 Aug 2021.